(Q33401360)

26 July 2017

title

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia (English)

1 reference

26 July 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Kimmo Porkka

4

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

5

0 references

author name string

Juan Luis Steegmann

1

1 reference

26 July 2017

Francisco Cervantes

2

1 reference

26 July 2017

Philipp le Coutre

3

1 reference

26 July 2017

publication date

18 June 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

53

1 reference

26 July 2017

issue

12

1 reference

26 July 2017

page(s)

2351-2361

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

c-Abl tyrosine kinase regulates cardiac growth and development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Severe peripheral arterial disease during nilotinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib as a possible cause of severe rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Gynaecomastia in men with chronic myeloid leukaemia after imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The skeletal effects of the tyrosine kinase inhibitor nilotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Decreased c-Src expression enhances osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Bcl-2 reduced and fas activated by the inhibition of stem cell factor/KIT signaling in murine melanocyte precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib mesylate as a cause of acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib-induced acute hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Acute renal failure under dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

ABL1 fusion genes in hematological malignancies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.695779

10.3109/10428194.2012.695779

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference